RecruitingNCT05623956
Proteomics in Small Cell Lung Cancer
Circulating Metabolites and Tumor-derived Extravesicular Proteins in Small Cell Lung Cancer
Sponsor
Aalborg University Hospital
Enrollment
50 participants
Start Date
Mar 1, 2023
Study Type
OBSERVATIONAL
Conditions
Summary
The aim of this study is to gather insight into tumor-derived circulating extracellular vesicles-proteins in patients with newly diagnosed small cell lung cancer.
Eligibility
Min Age: 18 Years
Inclusion Criteria4
- Written and signed informed consent
- Histopathologically and/or cytologically newly-diagnosed SCLC
- Measurable disease on CT scans
- Eligibility to receive standard chemotherapy consisting of carboplatin and etoposide
Exclusion Criteria4
- Active biopsy-verified second malignancy other than non-melanoma skin cancer or cervical carcinoma in situ
- Prior treatment for any malignant diseases other than non-melanoma skin cancer and cervical carcinoma in situ
- Concomitant anticoagulation treatment (acetylsalicylic acid and clopidogrel are allowed)
- Treatment with any other investigational agent
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05623956
Related Trials
A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer
NCT0715517416 locations
A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (MK-6070-002)
NCT0678013745 locations
A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors
NCT0625726424 locations
A Study of AK112 as Consolidation Treatment for Patients With Limited Stage Small-cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation Therapy
NCT0701026353 locations
A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer
NCT06203210230 locations